• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Clindamycin Injection
    / Rafa

    Active Ingredient

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    5 X 4 ml X 150 mg/ml

    partial basket chart 3908 3955


    Parenteral (IM or IV) administration: Serious infections due to aerobic gram-positive cocci and the more susceptible anaerobes (NOT generally including Bacteroides fragilis, Peptococcus species and Clostridium species other than
    Clostridium perfringens): 600-1200 mg/day in 2, 3, or 4 equal doses.
    More severe injections, particularly those due to proven or suspected Bacteroides fragilis, Peptococcus species, or Clostridium species other than Clostridium perfringens: 1200-2700 mg/day in 2, 3, or 4 equal doses.
    For more serious infections these doses may have to be increased. In life-threatening situations due to either aerobes or anaerobes these doses may be increased. Doses of as much as 4800 mg daily have been given intravenously to adults.
    Single IM injections of greater than 600 mg are not recommended.
    See prescribing information for full details.
    Elderly patients: The half-life, volume of distribution and clearance, and extent of absorption after administration of clindamycin phosphate are not altered by increased age. Analysis of data from clinical studies has not revealed any age-related increase in toxicity. Dosage requirements in elderly patients should not be influenced, therefore, by age alone.
    However, other reported clinical experience indicates that antibiotic-associated colitis and diarrhea (due to Clostridium difficile) seen in association with most antibiotics occur more frequently in the elderly (>60 years) and may be more severe. These patients should be carefully monitored for the development of diarrhea.
    Dosage in Renal/Hepatic Impairment: clindamycin dosage modification is not necessary in patients with renal or hepatic insufficiency.
    See prescribing information for full details.


    Treatment of serious infections caused by susceptible anaerobic bacteria and susceptible strains of streptococci, pneuomococci and staphylococci.


    Clindamycin is contra-indicated in patients previously found to be sensitive to clindamycin, lincomycin or to any component of the formulation, particularly benzyl alcohol.

    Special Precautions

    Serious anaphylactoid reactions require immediate emergency treatment. Benzyl alcohol has been associated with a fatal “Gasping Syndrome” in premature infants. Safety and appropriate dosages in infants less than one month old have not been established. Patients age 65 and over should be carefully monitored for the development of diarrhea. History of gastrointestinal disease, particularly colitis. Atopic individuals. Should not be injected intravenously undiluted as a bolus. Pseudomembranous colitis has been reported with nearly all antibacterial agents including clindamycin, and may range in severity from mild to life-threatening.

    Side Effects

    Antibiotic-associated colitis, abdominal pain, nausea, maculopapular rash, urticaria, generalized mild to moderate morbilliform-like skin rashes. A few cases of anaphylactoid reactions have been reported. Vaginitis, abnormalities in liver function tests. Transient neutropenia and eosinophilia.

    Drug interactions

    Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. It should be used with caution, therefore, in patients receiving such agents.
    Antagonism has been demonstrated between clindamycin and erythromycin in vitro. Because of possible clinical significance, the two medicines should not be administered concurrently.
    Vitamin K antagonists: Increased coagulation tests (PT/INR) and/or bleeding have been reported in patients treated with clindamycin in combination with a vitamin K antagonist (e.g. warfarin, acenocoumarol and fluindione). Coagulation tests, therefore, should be frequently monitored in patients treated with vitamin K antagonists.

    Rafa Laboratories Ltd.